Herborium(R) Group Discusses an Aftermath of the Ban of Diane-35
Acne Drug Due to Number of Deaths
FORT LEE, N.J., Feb. 4, 2013 /PRNewswire/ -- Herborium
Group, Inc., (OTC Pink: HBRM) www.herborium.com, a Botanical
Therapeutics® Company discusses an impact of a ban of Bayer's
Diana-35 acne drug in Europe, and
a follow up investigation in Canada, on Herborium' s all
botanical acne treatment -AcnEase®.
Diane-35 is a hormonal drug used to treat hormonal acne,
especially those resulting from too much of androgens (male
hormones). It is also an oral contraceptive (birth control pill).
Diane-35 is not approved in the US but it was available in
Canada. Like many other drugs
Diane-35 found its way to US consumers though so called "gray
marketing".
Diane-35 is presently investigated in Europe and Canada for number of deaths, caused by blood
clots, and for non-fatal cases of thrombosis and arterial
thrombosis associated with a use of a drug.
In September 2011, the U.S. Food
and Drug Administration (FDA) has informed the public that it has
not yet reached a conclusion, but remains concerned, about the
potential increased risk of blood clots with the use of
drospirenone-containing birth control pills. Number of US
approved contraceptive pills including very popular Yasmin and Yuz
were put on a warning list. Despite of the warning,
birth control pills are still rather liberally prescribed to
women with acne even if their sexual activity is not a
factor.
AcnEase® is all botanical ingredients based product that DOES
NOT INCLUDE ANY ESTROGEN. Furthermore, AcnEase® also DOES NOT
include any phytoestrogens (plant-derived estrogen-like
substance). As phytoestrogens may be considered safer that those
made chemically they still act in a similar way and therefore may
not be suitable or safe for some consumers especially teens, women
that want to become pregnant, those who are pregnant or nursing,
and of course men suffering from hormonal acne.
"We are deeply saddened by a death and potential serious health
implication among Diane-35 patients. We are also determined to
reiterate to our investors and customers that a decision to base
Herborium's differential advantage on the use of proprietary,
validated and safe botanical formulas has once again been proven
correct and most advantageous both strategically and ethically. We
will continue to provide safe and up to 96% effective AcnEase® to
acne sufferers in all markets, and to grow our market share in the
multi-billion dollar world-wide acne treatment
sector," commented Dr. Agnes P.
Olszewski, CEO and Chairwomen of Herborium
Group.
About Herborium Group, Inc.
Herborium Group, Inc., a Botanical Therapeutics® company,
focuses on developing, licensing, and marketing proprietary,
botanical based medicinal products to consumers and healthcare
professionals. The Company uses clinical validation to
establish and maintain a differential advantage. The company
sells its products in the US and Europe. For more information, please visit
www.herborium.com and www.acnease.com
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time, and we disclaim any obligation to update or
alter forward-looking statements as the result of new information
or future events. The Company urges investors to review the risks
and uncertainties contained within its filings with the OTC Markets
and/or Securities and Exchange Commission.
For more information please inquire:
Investorsrelations@herborium.com
SOURCE Herborium Group, Inc.